Antisense studies of brain GABAA receptors

Danish Medical Bulletin

Volumn 49, Issue 2, 2002, Pages 130-144

  Karle, Jesper ^a  

^a NONE   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID A RECEPTOR; ANTISENSE OLIGODEOXYNUCLEOTIDE; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; BRAIN RECEPTOR; MESSENGER RNA; NEUROTRANSMITTER; SINGLE STRANDED DNA; ANTISENSE OLIGONUCLEOTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DEGENERATIVE DISEASE; EPILEPTIC STATE; EPILEPTOGENESIS; GABAERGIC SYSTEM; GENE EXPRESSION; GENE TECHNOLOGY; HIPPOCAMPUS; LIMBIC CORTEX; NERVE CELL NECROSIS; NEUROTRANSMISSION; NONHUMAN; PATHOPHYSIOLOGY; RAT; TEMPORAL LOBE EPILEPSY; ANIMAL; BRAIN; ELECTROENCEPHALOGRAPHY; EPILEPSY; GENETICS; METABOLISM; PHYSIOLOGY; REVIEW;

ANIMAL; BRAIN; ELECTROENCEPHALOGRAPHY; EPILEPSY; GENE EXPRESSION; OLIGONUCLEOTIDES, ANTISENSE; RATS; RECEPTORS, GABA-A; ANIMALS;

EID: 0036000269     PISSN: 09078916     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (209)

1. Sequence-independent effects of phosphorothioated oligonucleotides on synaptic transmission and excitability in the hippocampus in vivo
2. Antisense oligonucleotides: Towards clinical trials
3. Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice
4. Cellular uptake and intracellular fate of antisense oligonucleotides
5. 2s subunits produce unique ion channels with dissimilar single-channel properties
6. A receptor deduced from mutation-induced rectification
7. A receptors: Classification on the basis of subunit structure and receptor function
8. Dormancy of inhibitory interneurons in a model of temporal lobe epilepsy
9. Limbic seizure and brain damage produced by kainic acid: Mechanisms and relevance to human temporal lobe epilepsy
10. A receptors in the brain
11. A receptors display association of γ2-subunit with α1- and β2/3-subunits
12. Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides
13. Inhibition of protein-tyrosine kinase activity in intact cells by the aptameric action of oligodeoxynucleotides
14. Ligand-gated ion channels in the brain: The amino acid receptor superfamily
15. 3H]GABA in nerve terminals of rat cerebral cortex by electronmicroscopic autoradiography
16. Chimeric alpha-beta oligonucleotides as antisense inhibitors of reverse transcription
17. Inhibition of translation initiation by antisense oligonucleotides via an RNase independent mechanism
18. Benzodiazepine receptor synthesis and degradation by neurons in culture
19. The "ABC" of GABA receptors
20. Interaction of convulsive ligands with benzodiazepine receptors
21. A Hitchhiker's guide to antisense and nonantisense biochemical pathways
22. A good antisense molecule is hard to find
23. Antisense oligonucleotides induce functional deletion of ligand gated ion channels in cultured neurons and brain explants
24. A receptor α subunits in cultured visual cortex slices reduces amplitude of evoked inhibitory postsynaptic currents
25. A receptor subtypes: From pharmacology to molecular biology
26. Oligodeoxynucleoside phosphorothioate stability in subcellular extracts, culture media, sera and cerebrospinal fluid
27. Comparative inhibition of rabbit globin mRNA translation by modified antisense oligodeoxynucleotides
28. The application of antisense oligonucleotide technology to the brain: Some pitfalls
29. Putative roles for the inducible transcription factor c-fos in the central nervous system: Studies with antisense oligonucleotides
30. Antisense oligonucleotide eliminates in vivo expression of c-fos in mammalian brain
31. Assembly and cell surface expression of heteromeric and homomeric γ-aminobutyric acid type A receptors
32. In vitro pharmacokinetics of phosphorothioate antisense oligonucleotides
33. Progress in antisense therapeutics
34. GABA bicuculline and central inhibition
35. Pharmacological inhibition of dopaminergic and other neurotransmitter receptors using antisense oligodeoxynucleotides
36. Introduction to temporal lobe epilepsy
37. Short antisense oligonucleotide-mediated inhibition is strongly dependent on oligo length and concentration but almost independent of location of the target sequence
38. A receptor
39. Five subtypes of type A γ-aminobutyric acid receptors identified in neurons by double and triple immunofluorescence staining with subunit-specific antibodies
40. A receptor heterogeneity in the adult rat brain: Differential regional and cellular distribution of seven major subunits
41. Phosphorothioate oligonucleotides are inhibitors of human DNA polymerases and RNase H: Implications for antisense technology
42. Gene-targeting studies of mammalian behavior: Is it the mutation or the background genotype?
43. Nucleic acid therapeutics: State of the art and future prospects
44. Oligodeoxynucleotides as antisense inhibitors of gene expression
45. Integration of molecular biological techniques and behavioural pharmacology
46. Ion-channel assembly
47. 2 subunit gene of γ-aminobutyric acid type A receptors
48. Antisense has growing pains
49. Picrotoxin-induced epileptiform activity in hippocampus: Role of endogenous versus synaptic factors
50. Novel anxiolytics that act as partial agonists at benzodiazepine receptors
51. Translation arrest by oligodeoxy-nucleotides complementary to mRNA coding sequences yields polypeptides of predetermined length
52. Antisense oligonucleotides for central nervous system tumours
53. Antisense as an explanatory, experimental and therapeutic tool for psychiatric disorders
54. Antisense technology; prospects for treatment of neuropsychiatric disorders
55. Antisense oligodeoxynucleotides as novel neuropharmacological tools for selective expression blockade in the Brain
56. Specific regulation of gene expression by antisense, sense and antigene nucleic acids
57. The third γ sub-unit of the γ-aminobutyric acid type A receptor family
58. Mapping of RNA accessible sites for antisense experiments with oligonucleotide libraries
59. Potent antisense oligonucleotides to the human multidrug resistance-1 mRNA are rationally selected by mapping RNA-accessible sites with oligonucleotide libraries
60. Mice devoid of γ-aminobutyric acid type A receptor β3 subunit have epilepsy, cleft palate, and hypersensitive behavior
61. Infusion into the brain of an antisense oligonucleotide to the immediate-early gene c-fos suppresses production of fos and produces a behavioral effect
62. Selective antagonists of benzodiazepines
63. A receptor sub-unit requires a monomeric subunit of α6 or γ2
64. Targeting of anti-sense DNA: Comparison of activity of anti-rabbit β-globin oligodeoxy-ribonucleoside phosphorothioates with computer predictions of mRNA folding
65. A receptor pharmacology
66. A receptors
67. A receptor γ2 subunit
68. A receptor γ2 subunit subtype
69. The mechanism of action and pharmacology of zopiclone
70. A receptors with antisense oligonucleotides - Implications for epilepsy
71. A receptor γ2 subunit induces loss of neurones in rat hippocampus
72. A receptor γ2 subunit
73. A receptors
74. A receptor γ2 subunit into rat hippocampus
75. A receptor γ2 subunit induces limbic status epilepticus
76. Epilepsy in mice deficient in the 65-kDa isoform of glutamic acid decarboxylase
77. Neuropeptide Y suppresses epileptiform activity in rat hippocampus in vitro
78. Regulation of gene expression by natural antisense transcripts
79. A receptor subtypes
80. Antisense properties of duplex- and triplex-forming PNAs
81. GABA(A)-receptor subtypes: Clinical efficacy and selectivity of benzodiazepine site ligands
82. Phosphorothioate oligodeoxynucleotides: Antisense or anti-protein?
83. CpG motifs in bacterial DNA trigger direct B-cell activation
84. Antisense targeting in behavioural neuroendocrinology
85. V1 vasopressin receptor antisense oligodeoxynucleotide into septum reduces vasopressin binding, social discrimination abilities, and anxiety-related behavior in rats
86. Neuroendocrine and behavioral effects of antisense oligonucleotides
87. A receptor subunit mRNAs in the rat brain. II. Olfactory bulb and cerebellum
88. A receptor subunit mRNAs in the rat brain. III. Embryonic and postnatal development
89. Critical issues in the antisense inhibition of brain gene expression in vivo: Experiences targetting the 5-HT1A receptor
90. Cell delivery and mechanisms of action of antisense oligonucleotides
91. Characterization of oligonucleotide transport into living cells
92. A/benzodiazepine receptor heterogeneity: Neurophysiological implications
93. Impact of β and γ variants on ligandbinding properties of γ-aminobutyric acid type A receptors
94. GABAmimetics in animal models of seizure states
95. The role of technical, biological, and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. II. Maximal electroshock seizure models
96. The role of technical, biological, and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. III. Pentylenetetrazole seizure models
97. Antiepileptic drug mechanisms of action
98. A receptor channels
99. Chemical and electrical stimulation of hippocampus in unrestrained animals. I. Methods and electroencephalographic findings
100. The Limbic System Concept
101. Knockout mice
102. A receptor-mediated synaptic potentials underlie enhanced CA1 excitability in a chronic model for temporal lobe epilepsy
103. B receptors - The first 7TM heterodimers
104. A receptors
105. Antisense oligodeoxynucleotides in behavioral neuroscience
106. 67 mRNAs modulate reproductive behavior in the female rat
107. A receptor subtypes really occur in the brain?
108. Cellular and molecular basis of epilepsy
109. A receptors
110. GABAergic mechanisms in the pathogenesis and treatment of epilepsy
111. Excitotoxins, limbic pathology and excitatory amino acid antagonists
112. Epilepsy
113. Backbone modifications in oligonucleotides and peptide nucleic acid systems
114. A receptor γ2 subunit enhances neuropeptide Y (NPY) gene expression
115. Electroconvulsive shocks increase the expression of neuropeptide Y (NPY) mRNA in the piriform cortex and the dentate gyrus
116. Control of ribonucleic acid function by oligonucleoside methylphosphonates
117. The use of single-stranded DNA and RNase H to promote quantitative "hybrid arrest of translation" of mRNA/DNA hybrids in reticulocyte lysate cell-free translations
118. A/benzodiazepine receptors
119. Ion channels in epilepsy
120. Benzodiazepine receptor: Demonstration in the central nervous system
121. Sensible use of antisense: How to use oligonucleotides as research tools
122. A receptor determined by electron microscopic image analysis
123. Antisense oligonucleotides in neuroendocrinology: Enthusiasm and frustration
124. Antisense oligodeoxynucleotides as specific tools for studying neuroendocrine and behavioral functions: Some prospects and problems
125. Ethyl-β-carboline-3-carboxylate shows differential benzodiazepine receptor interaction
126. Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide
127. Targeting epilepsy genes
128. Current status of antisense DNA methods in behavioral studie
129. Microinjection of antisense c-mos oligonucleotides prevents meiosis II in the maturing mouse egg
130. GABA and epileptogenesis
131. Sequence-independent induction of sptranscription factor activity by phosphorothioate oligodeoxynucleotides
132. Intracerebroventricular administration of missense oligodeoxynucleotide induces interleukin-6 mRNA expression in brain and spleen of rats
133. Applications of antisense oligonucleotides in oncology
134. Abenzodiazepine receptors produced in transfected cells
135. A receptor subunit for benzodiazepine pharmacology
136. Elevated messenger RNA levels after antisense oligodeoxynucleotide treatment in vitro and in vivo
137. Inhibitory, GABAergic nerve terminals decrease at sites of focal epilepsy
138. A receptor isoform
139. Automation of the social interaction test by a video-tracking system: Behavioural effects of repeated phencyclidine treatment
140. Regulation of serotonin2A receptor expression by an antisense oligodeoxynucleotide
141. A receptor shows a ligand-gated receptor super-family
142. Centrally administered oligodeoxynucleotides in rats: Occurrence of non-specific effects
143. A receptor family: Molecular and functional diversity
144. Antisense technologies have a future fighting neurodegenerative diseases
145. γ-aminobutyric acid A or C receptor? γAminobutyric acid p1 receptor RNA induces bicuculline-, barbiturate-, and benzodiazepine-insensitive γ-aminobutyric acid responses in xenopus oocytes
146. A receptor subunits exist in distinct neuronal subpopulations
147. Structure and pharmacology of γ-aminobutyric acidA receptor subtypes
148. Decreased hippocampal inhibition and a selective loss of interneurons in experimental epilepsy
149. On the relationship between neuropathology and pathophysiology in the epileptic hippocampus of humans and experimental animals
150. Permanently altered hippocampal structure, excitability, and inhibition after experimental status epilepticus in the rat: The "Dormant Basket Cell" hypothesis and its possible relevance to temporal lobe epilepsy
151. A receptors are differentially sensitive to zinc: Dependence on subunit composition
152. Rational selection of antisense oligonucleotide sequences
153. A receptor α4 subunit suppression prevents withdrawal properties of an endogenous steroid
154. Functional changes in neuropeptide Y- and somatostatin-containing neurons induced by limbic seizures in the rat
155. A receptor subunits in the rat hippocampus I: Immunocytochemical distribution of 13 subunits
156. Benzodiazepine receptors in rat brain
157. Selective loss of δ opioid analgesia and binding by antisense oligonucleotides to a δ opioid receptor
158. Does antisense exist?
159. Phosphorothioate antisense oligodeoxynucleotides: Questions of specificity
160. Is irrelevant cleavage the price of antisense efficacy?
161. Antisense oligonucleotides as therapeutic agents - Is the bullet really magical?
162. Problems in interpretation of data derived from in vitro and in vivo use of antisense oligodeoxynucleotides
163. Physicochemical properties of phosphorothioate oligodeoxynucleotides
164. A receptors
165. A receptor but the α1 polypeptide is the principal site of the agonist benzodiazepine photoaffinity labeling reaction
166. Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide
167. Predicting antisense oligonucleotide inhibitory efficacy: A computational approach using histograms and thermodynamic indices
168. 1231]iomazenil SPECT imaging demonstrates significant benzodiazepine receptor reserve in human and nonhuman primate brain
169. Antisense oligonucleotides against transcription factor Zif 268 transiently impair excitatory synaptic transmission in the hippocampus without affecting Zif 268 immunoreactivity
170. Antisense oligodeoxyribonucleotides: Stability and distribution after intracerebral injection into rat brain
171. Pharmacokinetics of antisense analogues in the central nervous system
172. GABAergic modulation of benzodiazepine binding site sensitivity
173. Antisense oligonucleotides: A new therapeutic approach
174. Electroclinical features of status epilepticus
175. Status epilepticus
176. Antisense oligonucleotides: A new therapeutic principle
177. Antisense: Chemical modifications
178. A receptors depend upon subunit composition
179. Gene inhibition using antisense oligodeoxynucleotides
180. Antisense gene inhibition by oligonucleotides containing C-5 propyne pyrimidines
181. Antisense oligonucleotide strategies in neuropharmacology
182. Antisense "knockdown" strategies in neurotransmitter receptor research
183. Antisense oligodeoxynucleotides to NMDA-R1 receptor channel protect cortical neurons from excitotoxicity and reduce focal ischaemic infarctions
184. Modulation of anxiety and neuropeptide Y-Y1 receptors by antisense oligodeoxynucleotides
185. Potent and nontoxic antisense oligonucleotides containing locked nucleic acids
186. Role of RNase H in hybrid-arrested translation by antisense oligonucleotides
187. Antisense strategies in neurobiology
188. Antisense oligodeoxynucleotide inhibits D2 dopamine receptor-mediated behavior and D2 messenger RNA
189. Stability, clearance, and disposition of intraventricularly administered oligodeoxynucleotides: Implications for therapeutic application within the central nervous system
190. A receptor subunit conferring atypical functional properties
191. Another mechanism for creating diversity in γ-aminobutyrate type A receptors: RNA splicing directs expression of two forms of γ2 subunit, one which contains a protein kinase C phosphorylation site
192. A receptor α-subunit mRNA do not correlate during development
193. A receptor subunit mRNAs in the rat brain. I. Telencephalon, diencephalon, mesencephalon
194. Powerful inhibition of kainic acid seizures by neuropeptide Y via Y5-like receptors
195. Specificity of antisense oligonucleotides in vivo
196. A α1 containing receptors and increases inferior collicular seizure sensitivity
197. Distribution of phosphodiester and phosphorothioate oligonucleotides in rat brain after intraventricular and intrahippocampal administration determined by in situ hybridization
198. Mechanism of oligonucleotide uptake by cells: Involvement of specific receptors?
199. Cellular uptake of intracerebroventricularly administered biotin- or digoxigenin-labeled antisense oligodeoxynucleotides in the rat
200. A/benzodiazepine receptors
201. B receptors in mammalian brain: Potential targets for drug development
202. Do nonconvulsive seizures damage the brain? - Yes
203. Uptake of antisense oligonucleotides and functional block of acetylcholine receptor subunit gene expression in primary embryonic neurons
204. Antisense oligodeoxynucleotide reduces brain dopamine D2 receptors: Behavioral correlates
205. A receptor gamma-2 subunit
206. A receptor γ2 subunit increases convulsive threshold for β-CCM, a benzodiazepine 'inverse agonist', in rats
207. In vivo administration of an oligodeoxynucleotide antisense to the D2 dopamine receptor messenger RNA inhibits D2 dopamine receptor-mediated behavior and the expression of D2 dopamine receptors in mouse striatum
208. α6 and γ2 subunit antisense oligodeoxynucleotides alter γ-aminobutyric acid receptor pharmacology in cerebellar granule neurons
209. Antisense phosphorothioate oligodeoxynucleotides: Introductory concepts and possible molecular mechanisms of toxicity